首页> 美国卫生研究院文献>Genes >Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension
【2h】

Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension

机译:定制肺动脉高压诊断的大规模平行测序板

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pulmonary arterial hypertension is a very infrequent disease, with a variable etiology and clinical expressivity, making sometimes the clinical diagnosis a challenge. Current classification based on clinical features does not reflect the underlying molecular profiling of these groups. The advance in massive parallel sequencing in PAH has allowed for the describing of several new causative and susceptibility genes related to PAH, improving overall patient diagnosis. In order to address the molecular diagnosis of patients with PAH we designed, validated, and routinely applied a custom panel including 21 genes. Three hundred patients from the National Spanish PAH Registry (REHAP) were included in the analysis. A custom script was developed to annotate and filter the variants. Variant classification was performed according to the ACMG guidelines. Pathogenic and likely pathogenic variants have been found in 15% of the patients with 12% of variants of unknown significance (VUS). We have found variants in patients with connective tissue disease (CTD) and congenital heart disease (CHD). In addition, in a small proportion of patients (1.75%), we observed a possible digenic mode of inheritance. These results stand out the importance of the genetic testing of patients with associated forms of PAH (i.e., CHD and CTD) additionally to the classical IPAH and HPAH forms. Molecular confirmation of the clinical presumptive diagnosis is required in cases with a high clinical overlapping to carry out proper management and follow up of the individuals with the disease.
机译:肺动脉高压是一种非常少量的疾病,具有可变病因和临床表征,有时临床诊断是挑战。基于临床特征的当前分类不反映这些组的潜在分子分析。 PAH中大规模平行测序的进展允许描述与PAH相关的几种新的致病和易感基因,改善整体患者诊断。为了解决PAH患者的分子诊断,我们设计,验证,经常应用了包括21个基因的定制面板。来自国家西班牙语PAH登记处(再清波)的三百名患者被列入分析。开发了一种自定义脚本以批注和过滤变量。根据ACMG指南进行变体分类。在15%的患者中发现了致病性和可能的​​致病变体,其患者的15%是未知意义(VUS)的含量为12%。我们发现了结缔组织疾病(CTD)和先天性心脏病(CHD)患者的变体。此外,在一小部分患者(1.75%),我们观察了可能的遗传模式。这些结果突出了患有相关形式的PAH(即,CHD和CTD)的患者的遗传测试的重要性,另外到古典的IPAH和HPAH形式。在具有高临床重叠的情况下,需要临床推定诊断的分子确认,以进行适当的管理和对疾病的个体的跟进。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号